Stuttgart - Delayed Quote EUR

Agios Pharmaceuticals Inc (8AP.SG)

31.40

0.00

(0.00%)

As of 8:00:44 AM GMT+1. Market Open.

Is Agios Pharmaceuticals, Inc. (AGIO) the Best Small-Cap Stock to Buy Now?

We recently published a list of the 10 Best Small-Cap Stocks to Buy Now. In this article, we are going to take a look at where Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) stands against the other small-cap stocks. The S&P 500 index has reached its all-time highs, achieving returns of over 20% for the second consecutive year […]

Insider Monkey 2 days ago

AGIO

^GSPC

^RUT
Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025

CAMBRIDGE, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the TD Cowen 45th Annual Healthcare Conference on Monday, March 3, 2025, at 10:30 a.m. ET. The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the “Events & Presentations” tab. A replay of t

GlobeNewswire 11 days ago

AGIO
Agios Pharmaceuticals price target lowered to $74 from $75 at Scotiabank

Scotiabank lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $74 from $75 and keeps an Outperform rating on the shares. The firm is impressed by the company’s regulatory and clinical execution in Q4, the analyst tells investors. Scotiabank believes Agios is well-equipped to accelerated growth of the Pyrukynd franchise and remains cautiously optimistic on mitapivat’s point of sickening. Published first on TheFly – the ultimate source for real-time, market-moving breaking financia

TipRanks 16 days ago

AGIO
Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues

AGIO reports mixed fourth-quarter 2024 results. Its sole marketed drug, Pyrukynd, drives revenues year over year.

Zacks 17 days ago

AGIO
Agios Pharmaceuticals Full Year 2024 Earnings: Beats Expectations

Agios Pharmaceuticals ( NASDAQ:AGIO ) Full Year 2024 Results Key Financial Results Revenue: US$36.5m (up 36% from FY...

Simply Wall St. 17 days ago

AGIO
Agios Pharmaceuticals Inc (AGIO) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ...

Agios Pharmaceuticals Inc (AGIO) reports a 51% increase in net Pyrukynd revenue and outlines promising future launches and clinical advancements.

GuruFocus.com 18 days ago

AGIO
Agios Pharmaceuticals Reveals Encouraging Data From Rare Blood Disorder Study In Younger Patients Aged Below 18 Years

On Thursday, Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced that the ACTIVATE-Kids Phase 3 study of mitapivat in children aged 1 to <18 years with PK deficiency who are not regularly transfused achieved its primary endpoint of hemoglobin response. Pyruvate kinase (PK) deficiency is a rare, inherited disorder that affects red blood cells. The safety results were consistent with the safety profile for mitapivat previously observed for adult patients with PK deficiency who are not regularly tr

Benzinga 18 days ago

AGIO
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -0.58% and 11.76%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 18 days ago

AGIO
Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

– Filed for Regulatory Approval of Mitapivat (PYRUKYND®) for the Treatment of Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia in U.S., European Union, Kingdom of Saudi Arabia and United Arab Emirates; PDUFA Goal Date of September 7, 2025 – – Completed Enrollment for Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease; Topline Results Expected in Late 2025, with Potential U.S. Commercial Launch in 2026 – – Early- and Mid-Stage Pipeline Offe

GlobeNewswire 18 days ago

AGIO
Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

– ACTIVATE-Kids is the First Study to Demonstrate Efficacy of an Oral Therapy for Children with PK Deficiency Who Are Not Regularly Transfused – – Safety Results Consistent with Safety Profile for Mitapivat Previously Observed in Adults with PK Deficiency Who Are Not Regularly Transfused – – First Mitapivat Pediatric Clinical Program for a Rare Hemolytic Anemia; Double-blind Period Completed for Both PK Deficiency Trials ACTIVATE-Kids and ACTIVATE-KidsT – CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE N

GlobeNewswire 18 days ago

AGIO
Agios Pharmaceuticals price target lowered to $54 from $55 at BofA

BofA lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $54 from $55 and keeps a Buy rating on the shares. The firm sees Agios’ story “gaining traction over the next 12 months” and cites slightly reduced outer-year revenue expectations, offset by reduced expenses, for its revised target on the shares. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on AGIO: AGIO

TipRanks 19 days ago

AGIO
Agios Pharmaceuticals, Inc. (AGIO): A Cheap Biotech Stock to Invest In Now

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at where Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) stands against the other cheap biotech stocks. Biotech Stocks Face Uncertainty Despite Interest Rate Cuts Biotechnology stocks are among the most volatile in the market […]

Insider Monkey 19 days ago

AGIO
Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, February 13, 2025, at 8:00 a.m. ET to report its fourth quarter and full year 2024 financial results and business highlights. The live webcast will be accessible on the Investors section of the company’s websit

GlobeNewswire 25 days ago

AGIO
Why Agios Pharmaceuticals (AGIO) Is the Top Small Cap Stock to Buy with the Highest Upside Potential

We recently published a list of the Top 10 Small Cap Stocks to Buy with the Highest Upside Potential. In this article, we are going to take a look at where Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) stands against other top small cap stocks to buy with the highest upside potential. What Would 2025 Look Like for […]

Insider Monkey last month

AGIO
Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio

– FDA Accepted Agios’ Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia; PDUFA Goal Date is September 7, 2025 – – Topline Results from Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease to be Announced in Late 2025, with Potential U.S. Commercial Launch in 2026 – – Strong Financial Position Provides Opportunity to Maximize Potential PYRUKYND Commercial Launches, Advance Early- a

GlobeNewswire last month

AGIO
FDA Accepts Agios' sNDA for Pyrukynd in Thalassemia

If approved, AGIO's Pyrukynd will be the first oral therapy for all thalassemia subtypes. A final decision is expected by Sep. 7.

Zacks last month

AGIO

CSTL
FDA Accepts Agios’ Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia

CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) accepted the company’s supplemental New Drug Application (sNDA) for PYRUKYND® (mitapivat) for the treatment of adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia. The review classific

GlobeNewswire last month

AGIO
How to Navigate the Stock and Bond Markets in 2025

We asked 10 investing and economic experts for their recommendations as Donald Trump returns to power. Here’s what they said.

The Wall Street Journal last month

CGON

AMZN

KOS
Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

CAMBRIDGE, Mass., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 7:30 a.m. PT / 10:30 a.m. ET. The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the “Events & Presentat

GlobeNewswire last month

AGIO
European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell Disease

CAMBRIDGE, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that the European Commission has adopted a positive decision for the designation of mitapivat, an oral, small molecule PK activator, as an orphan medicinal product (OMP) for the treatment of sickle cell disease. Earlier, in November 2020, the U.S. Food and Drug Administration (FD

GlobeNewswire 2 months ago

AGIO

Performance Overview

Return	8AP.SG	S&P 500
YTD	-0.63%	-0.54%
1-Year	+6.80%	+14.01%
3-Year	+7.24%	+35.13%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Agios Pharmaceuticals Inc (8AP.SG)

Is Agios Pharmaceuticals, Inc. (AGIO) the Best Small-Cap Stock to Buy Now?

Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025

Agios Pharmaceuticals price target lowered to $74 from $75 at Scotiabank

Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues

Agios Pharmaceuticals Full Year 2024 Earnings: Beats Expectations

Agios Pharmaceuticals Inc (AGIO) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ...

Agios Pharmaceuticals Reveals Encouraging Data From Rare Blood Disorder Study In Younger Patients Aged Below 18 Years

Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates

Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

Agios Pharmaceuticals price target lowered to $54 from $55 at BofA

Agios Pharmaceuticals, Inc. (AGIO): A Cheap Biotech Stock to Invest In Now

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Why Agios Pharmaceuticals (AGIO) Is the Top Small Cap Stock to Buy with the Highest Upside Potential

Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio

FDA Accepts Agios' sNDA for Pyrukynd in Thalassemia

FDA Accepts Agios’ Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia

How to Navigate the Stock and Bond Markets in 2025

Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell Disease

Performance Overview